How haemophilia A impacts severe acute respiratory syndrome coronarovirus 2 ( SARS-Cov-2) treatment: a case report
In this article, the authors describe the case of a mild hemophiliac patient suffering from Covid-19 pneumonia, focusing their attention on how the presence of hemophilia affects the management of COVID pneumonia. The typical symptoms of COVID-19 mimic those of the common season flu. In addition, several changes in the coagulation processes have been observed. […]
THE IMPACT OF COVID-19 PANDEMIC IN THE HEMOPHILIA COMMUNITY
Cedric Hermans, Alain Weill and Glenn F Pierce have published an article on the impact of COVID-19 pandemic in the hemophilia community (Haemophilia 2020 Apr 4. [Epub ahead of print]). The editorial focuses on the COVID-19 (SARS-COV-2) pandemic as a new global challenge for the hemophilia community. At present, they report, it is impossible to […]
Statement on the second meeting of the International Health Regulations Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV)
The second meeting of the Emergency Committee convened by the WHO Director-General under the International Health Regulations (IHR) (2005) regarding the outbreak of novel coronavirus 2019 took place on Thursday, 30 January 2020. China quickly identified the virus and shared its sequence, so that other countries are now able to diagnose it quickly and protect […]
Transmission of 2019-nCoV Infection from asymptomatic contacts in Europe and USA
Testo abstract:Coronavirus (2019-nCoV) from Wuhan is raising concerns in the health care community as the virus is spreading around the world. After being identified in late December 2019, the number of cases of Coronavirus (2019-nCoV) infections imported from China into other countries is increasing and its epidemiology is changing daily basis. In detail, in the […]
New physiotherapy concepts in hemophilia
Until the ’70s, hemophiliacs did not have great means and opportunities to improve the quality of life, they lived in a voluntary “segregation” due to a progressive disability, lacking therapeutic and rehabilitative supports properly for recovering physical activity . Subsequently, replacement therapy was developed with concentrates of the coagulation factors of which they were deficient […]
Physical exercise and rehabilitation in hemophilia
Physical exercise Physical exercise in patients with hemophilia (PWH) currently is used to heal faster after bleeding and to restore muscle-joint function in subjects with chronic arthropathy. Aquatic, stretching, proprioceptive and aerobic exercises are the most usual in PWH A and B of any severity. A Cochraine Database Systematic Review published in 2016 analyzed randomized […]
Bleeding and liver transplantation outcomes in haemophilia
Abstract BACKGROUND: Hepatitis C is the major cause of end-stage liver disease and the major indication for orthotopic liver transplantation (OLTx) in individuals with haemophilia. AIM: To assess the epidemiology and outcomes of OLTx in U.S. haemophilia patients. METHODS: We investigated haemophilia liver transplant recipients between 1993 and 2012, using the Nationwide Inpatient Sample, identified […]
12 June 2020
Emerging viral diseases and infectious disease risks
New pathogens and antimicrobial-resistant forms of older pathogens continue to emerge, some with the potential for rapid, global spread and high morbidity and mortality. Pathogens can emerge either through introduction into a new population or when the interaction with the vector changes; emergence is also influenced by microbiological adaptation and change, global travel patterns, domestic […]
17 March 2021
Management of COVID-19-associated coagulopathy in persons with haemophilia
The SARS-CoV-2 coronavirus-induced infection (COVID-19) can be associated with a coagulopathy mainly responsible for pulmonary microvasculature thrombosis and systemic thromboembolic manifestations. The pathophysiology and management of the COVID-19 coagulopathy are likely more complex in patients with inherited bleeding diseases such as haemophilia. These individuals might indeed present with both bleeding and thrombotic complications and require […]
17 January 2018
Epidemiological characteristics of human prion diseases
In the absence of specific therapies for human prion diseases, which are frequently associated with neurodegenerative disorders with fatal outcome, only an active surveillance can be used to monitor and prevent the transmission of such diseases. For this reason, starting from 1993, surveillance systems have been established in many countries. Moreover, there is urgent need […]
23 March 2021
The SISET (Italian Society of Internal Medicine provides some practical information for patients with thrombosis and serious bleeding diseases in case of COVID-19 vaccination
Patients on oral anticoagulant treatment and patients with severe bleeding diseases People being treated with anticoagulant therapy and patients with bleeding disorders have a generic contraindication to intramuscular injections due to the risk of hematoma. However, anticoagulant therapy is in most cases indicated for diseases that increase the risk of contracting the COVID-19 […]
15 March 2021
Target joint resolution in patients with haemophilia A receiving long‐term prophylaxis with BAY 94‐9027
BAY 94‐9027 (damoctocog alfa pegol; Jivi®; Bayer AG, Germany) is an extended half‐life B‐domain–deleted, site‐specifically PEGylated recombinant FVIII. Due to its prolonged half‐life, BAY 94‐9027 has the potential to maintain FVIII at a higher haemostatic level for longer periods versus standard‐acting agents.This longer half‐life also allows less frequent dosing, which in turn could help to […]